WT1 and acute myeloid leukemia: This study was performed again two years later on more patients, 17 in total, and among them, eight showed a complete response with a median relapse-free survival of 47 months.181 On this basis, this group reported a phase II trial about a DC-pulsed mRNA vaccine encoding WT1 as postremission treatment in 30 AML patients at high risk of relapse.182 Thirteen patients showed an antileukemic response, with five-year overall and relapse-free survival rates of 53.8% and 50%, respectively (7.7% and 30.8% in nonresponders, respectively).